Abstract
The incidence of coronary heart disease (CHD) peaks in the elderly population. In secondary and primary prevention trials, cholesterol-lowering therapy reduces risk for CHD in both older and younger participants. This benefit, therefore, can be extended to the elderly.
MeSH terms
-
Aged
-
Anticholesteremic Agents / therapeutic use
-
Cholesterol / blood*
-
Clinical Trials as Topic
-
Coronary Angiography
-
Coronary Disease / blood
-
Coronary Disease / diagnostic imaging
-
Coronary Disease / etiology
-
Coronary Disease / prevention & control*
-
Humans
-
Hypercholesterolemia / blood*
-
Hypercholesterolemia / complications
-
Hypercholesterolemia / drug therapy
-
Hypercholesterolemia / therapy*
-
Patient Selection
-
Risk Factors
-
Sex Factors
-
United States
Substances
-
Anticholesteremic Agents
-
Cholesterol